Escitalopram in employed people - Results from an observational study in 2378 patients;Escitalopram bei berufstätigen menschen - Ergebnisse einer anwendungsbeobachtung an 2378 patienten

Psychopharmakotherapie

Volumn 13, Issue 4, 2006, Pages 142-146

  Winkler, Dietmar ^a,b   Pjrek, Edda ^a,b   Klein, Nikolas ^a,b   Kasper, Siegfried ^a,b  

^a Währinger Gürtel 18 20 ^*

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antidepressants; Depression; Escitalopram; Sick leave

Indexed keywords

CITALOPRAM; ESCITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL LEAVE; OBSERVATIONAL STUDY; PANIC; SOCIAL PHOBIA; UNSPECIFIED SIDE EFFECT;

EID: 33747262615     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Auquier P, Robitail S, Llorca PM, Rive B. Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatry Clin Pract 2003;7:259-68.
2. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17:65-9.
3. Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005;15: 193-8.
4. Corruble E, Puech AJ. How to improve the risk-benefit ratio of antidepressants. Int Clin Psychopharmacol 1993;8:237-41.
5. Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27:111-24.
6. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001;3:22-7.
7. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23:155-67.
8. Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram. a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003;4:12-9.
9. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005;87:161-7.
10. Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education and Welfare publication (ADM). Rockville, MD: National Institute of Mental Health, 1976:76-338.
11. Hakkarainen H, Hattab JR, Venulet J. Phase IV research by pharmaceutical companies. Pharmacopsychiatry 1984;17:168-75.
12. Hauptverband der Österreichischen Sozialversicherungsträger. Handbuch der Österreichischen Sozialversicherung 2002. Wien: Österreichische Sozialversicherung, 2002.
13. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004;20:869-78.
14. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacomer 2004;38:954-60.
15. IMS Health. IMS Dataview. IMS data QTR/ 12/02, 2002.
16. Kasper S, Spadone C, Verpillat P, Angst J. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006;21:105-10.
17. Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005;186:222-6.
18. Klein N, Wiesegger G, Attarbaschi T, Winkler D, et al. A naturalistic observational study of escitalopram in the treatment of depression and anxiety disorder in adult outpatients. Rom J Psychopharmacol 2004;4:1-9.
19. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-7.
20. Linden M, Baier D, Beitinger H, Kohnen R, et al. Leitlinien zur Durchführung von Anwendungsbeobachtungen (AWB) in der Psychopharmakotherapie. Nervenarzt 1994;65:638-44.
21. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005;59:268-75.
22. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-50.
23. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-9.
24. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005;21:26-32.
25. SPSS for Windows. Release 11.0. Chicago, IL, USA: 1989-2001.
26. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003;64:1322-7.
27. Statistik Austria. Statistisches Jahrbuch, http: //www.statistik.at, 2003.
28. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;29:1102-9.
29. Wade A, Despiegel N, Reines E. Long-term treatment of depression with escitalopram is safe and well-tolerated. Eur Neuropsychopharmacol 2002;12(Suppl 3):232-3.
30. Wade A, Lemming OM, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102.
31. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005;27:486-96.
32. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005;21:631-42.
33. Wiener Gebietskrankenkasse. Wien: Gebietskrankenkasse, 2003.
34. Winkler D, Kasper S. Escitalopram. Arzneimitteltherapie 2004;22:97-102.
35. World Health Organization. The ICD-10 classification of mental and behavioral disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization (WHO), 1991.